S-Equol, an Antioxidant Metabolite of Soy Daidzein, and Oxidative Stress in Aging: A Focus on Skin and on the Cardiovascular System

Aging: Oxidative Stress and Dietary Antioxidants

Volumn , Issue , 2014, Pages 145-155

  Jackson, Richard L ^a   Greiwe, Jeffrey S ^a   Schwen, Richard J ^a  

^a Ausio Pharmaceuticals LLC   (United States)

Author keywords

Aging skin; Cardiovascular diseases; Estrogen; Estrogen receptor ; Isoflavones; Oxidative stress; S equol; Soy

Indexed keywords

EID: 84903014435     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-405933-7.00015-9     Document Type: Chapter

References (58)

1. Holland J., Bandelow S., Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas 2011, 69:322-337.
2. Ota H., Akishita M., Akiyoshi T., et al. Testosterone deficiency accelerates neuronal and vascular aging of SAMP8 mice: protective role of eNOS and SIRT1. PLoS One 2012, 10.1371/journal/pone.0029598.
3. Rossouw J.E. For the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
4. Coker L.H., Espeland M.A., Rapp S.R., et al. Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol 2010, 118:304-310.
5. Shumaker S.A., Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2947-2958.
6. Karim R., Dell R.M., Greene D.F., Mack W.J., Gallagher J.C., Hodis H.N. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011, 18:1172-1177.
7. Hodis H.N., Mack W.J. A 'window of opportunity': the reduction of coronary heart disease and total mortality with menopausal therapies is age - and time-dependent. Brain Res 2011, 1379:244-252.
8. Rocca W.A., Grossardt B.R., Shuster L.T. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res 2011, 1379:188-198.
9. Sherwin B.B. Estrogen therapy: is time of initiation critical for neuroprotection?. Nat Rev Endocrinol 2009, 5:620-627.
10. Shao H., Breitner J.C., Whitmer R.A., et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 2012, 79:1846-1852.
11. Zhao L., Brinton R.D. In search of estrogen alternative for the brain. Hormones, cognition and dementia: state of the art and emergent therapeutic strategies 2009, 93-100. Cambridge University Press, Cambridge. E. Hogervorst, V.W. Henderson, R.B. Gibbs, R.D. Brinton (Eds.).
12. Setchell K.D.R., Clerici C., Lephart E.D., et al. S-equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005, 81:1072-1079.
13. Jackson R.L., Greiwe J.S., Schwen R.J. Emerging evidence on the health benefits of S-equol, an estrogen receptor β agonist. Nutr Rev 2011, 69:432-438.
14. Ishiwata N., Melby M., Mizuno S., Watanabe S. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause 2009, 16:141-148.
15. Schwen R.J., Nguyen L., Jackson R.L. Elucidation of the metabolic pathway of S-equol in rat, monkey and man. Food Chem Toxicol 2012, 50:2074-2083.
16. Jackson R.L., Greiwe J.S., Desai P.B., Schwen R.J. Single-dose and multi-dose 14 day pharmacokinetics studies of S-equol, a potent non hormonal, estrogen receptor β agonist being developed for the treatment of menopausal symptoms. Menopause 2011, 18:185-193.
17. Velarde M.C., Flynn J.M., Day N.U., et al. Mitochondrial oxidative stress caused by Sod2 deficiency promotes cellular senescence and aging phenotypes in the skin. Aging 2012, 4:3-12.
18. Wend K., Wend P., Krum S.A. Tissue-specific effects of loss of estrogen during menopause and aging. Front Endocrinol (Lausanne) 2012, 3:1-19.
19. Archer D.F. Postmenopausal skin and estrogen. Gynecol Endocrinol 2012, 28:2-6.
20. Jackson R.L., Greiwe J.S., Schwen R.J. Aging skin: estrogen receptor β agonists offer a new approach to change the outcome. Exp Dermatol 2011, 20:879-882.
21. Hang M., Hamann T., Kulle A.E., et al. Age and skin site related differences in steroid metabolism in male skin point to a key role of sebocytes in cutaneous hormone metabolism. Dermatoendocrinol 2012, 4:58-64.
22. Markiewicz M., Znoyko S., Stawski L., et al. A role for estrogen receptorŁ and estrogen receptorŁ in collagen biosynthesis in mouse skin. J Invest Dermatol 2013, 133:120-127.
23. Chang K.C., Wang Y., Oh I.G., et al. Estrogen receptor beta is a novel therapeutic target for photoaging. Mol Pharmacol 2010, 77:744-750.
24. Lin J.Y., Tournas J.A., Burch J.A., et al. Topical isoflavones provide effective photoprotection to skin. Photodermatol Photoimmunol Photomed 2008, 24:61-66.
25. Reeve V.E., Widyarini S., Domanski D., et al. Protection against photoaging in the hairless mouse by the isoflavone equol. Photochem Photobiol 2005, 81:1548-1553.
26. Oyama A., Ueno T., Uchiyama S., et al. The effects of natural S-equol supplementation on skin aging in postmenopausal women: a pilot randomized placebo-controlled trial. Menopause 2012, 19:202-210.
27. Peres P.S., Terra V.A., Guarnier F.A., et al. Photoaging and chronological aging profile: understanding oxidation of the skin. J Photochem Photobiol B 2011, 103:93-97.
28. Ohtsuji M., Katsuoka F., Kobayashi A., et al. Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J Biol Chem 2008, 283:33554-33562.
29. Froyen E.B., Steinberg F.M. Soy isoflavones increase quinone reductase in hepa-1c1c7 cells via estrogen receptor beta and nuclear factor erythroid 2-related factor 2 binding to the antioxidant response element. J Nutr Biochem 2011, 22:843-848.
30. Choi E.J. Evaluation of equol function on anti - or prooxidant status in vivo. J Food Sci 2009, 74:H65-H71.
31. Jackman K.A., Woodman O.L., Sobey C.G. Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights. Curr Med Chem 2007, 14:2824-2830.
32. Yamori Y. CARDIAC study and dietary intervention studies, Chapter 6. Soy in health and disease prevention 2005, 107-119. CRC Press, New York. M. Sugano (Ed.).
33. Zhang X., Gao Y.T., Yang G., et al. Urinary isoflavonoids and risk of coronary heart disease. Int J Epidemiol 2012, 41:1367-1375.
34. Hodis H.N., Mack W.J., Kono N., et al. Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial. Stroke 2011, 42:3168-3175.
35. Cai Y., Guo K., Chen C., et al. Soya isoflavone consumption in relation to carotid intima-media thickness in Chinese equol excretors aged 40-65 years. Br J Nutr 2012, 29:1-7.
36. Clerici C., Setchell K.D., Battezzati P.M., et al. Pasta naturally enriched with isoflavone aglycons from soy germ reduces serum lipids and improves markers of cardiovascular risk. J Nutr 2007, 137:2270-2278.
37. Wong J.M., Kendall C.W., Marchie A., et al. Equol status and blood lipid profile in hyperlipidemia after consumption of diets containing soy foods. Am J Clin Nutr 2012, 95:564-571.
38. Hall W.L., Vafeiadou K., Hallund J., et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr 2005, 82:1260-1268.
39. Chan Y.H., Lau K.K., Yiu K.H., et al. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. Eur Heart J 2008, 29:2800-2807.
40. Hwang J., Wang J., Morazzoni P., et al. The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Radic Bio Med 2003, 34:1271-1282.
41. Richardson T.E., Simpkins J.W. R- and S-Equol have equivalent cytoprotective effects in Friedreich's ataxia. BMC Pharmacol Toxicol 2012, 13. 10.1186/2050-6411-13-12.
42. Chung J.E., Kim S.Y., Jo H.H., et al. Antioxidant effects of equol on bovine aortic endothelial cells. Biochem Biophys Res Comm 2008, 375:420-424.
43. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res 2011, 109:687-696.
44. Meyer M.R., Prossnitz E.R., Barton M. The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol 2011, 55:17-25.
45. Prossnitz E.R., Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011, 7:715-726.
46. Joy S., Siow R.C., Rowlands D.J., et al. The isoflavone equol mediates rapid vascular relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J Biol Chem 2006, 281:27335-27345.
47. Chapple S.J., Siow R.C., Mann G.E. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int J Biochem Cell Biol 2012, 44:1315-1320.
48. Siow R.C., Li F.Y., Rowlands D.J., et al. Cardiovascular targets for estrogens and phytoestrogens: transcriptional regulation of nitric oxide synthase and antioxidant defense genes. Free Radic Biol Med 2007, 42:909-925.
49. Mann G.E., Bonacasa B., Ishii T., Sio R.C.M. Targeting the redox sensitive Nrf2-Keap 1 defense pathway in cardiovascular disease: protection afforded by dietary isoflavones. Curr Opin Pharmacol 2009, 9:139-145.
50. Siow R.C., Mann G.E. Dietary isoflavones and vascular protection: activation of cellular antioxidant defenses by SERMs or hormesis?. Mol Aspects Med 2010, 31:468-477.
51. Yu J., Zhao Y., Li B., et al. 17β-estradiol regulates the expression of antioxidant enzymes in myocardial cells by increasing Nrf2 translocation. J Biochem Mol Toxicol 2012, 26:264-269.
52. Donovan E.L., McCord J.M., Reuland D.J., et al. Phytochemical activation of Nrf2 protects human coronary artery endothelial cells against an oxidative challenge. Oxid Med Cell Longev 2012, 10.1155/2012/132931.
53. Brydun A., Watari Y., Yamamoto Y., et al. Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis. Hypertens Res 2007, 30:341-348.
54. Huang X.S., Chen H.P., Yu H.H., et al. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for hypoxic preconditioning-mediated delayed cardioprotection. Mol Cell Biochem 2013, 10.1007/s11010-013-1812-6.
55. Rowlands D.J., Chapple S., Siow R.C., Mann G.E. Equol-stimulated mitochondrial reactive oxygen species activate endothelial nitric oxide synthase and redox signaling in endothelial cells: roles for F-actin and GPR30. Hypertension 2011, 57:833-840.
56. Hozawa A., Sugawara Y., Tomata Y., et al. Relationship between serum isoflavone levels and disability-free survival among community-dwelling elderly individuals: nested case-control study of the Tsurugaya Project. J Gerontol A Biol Sci Med Sci 2013, 68:465-472.
57. Todaka E., Sakurai K., Fukata H., et al. Fetal exposure to phytoestrogens-the difference in phytoestrogen status between mother and fetus. Environ Res 2005, 99:195-203.
58. Hong K.W., Ko K.P., Ahn Y., et al. Epidemiological profiles between equol producers and nonproducers: a genomewide association study of the equol-producing phenotype. Genes Nutr 2012, 7:567-574.